Arbutus Biopharma Corp. (NASDAQ:ABUS)’s share price dropped 1.5% during trading on Friday . The company traded as low as $3.71 and last traded at $3.93, with a volume of 139,359 shares. The stock had previously closed at $3.99.

ABUS has been the topic of a number of recent research reports. Leerink Swann reaffirmed a “buy” rating and set a $12.00 price target on shares of Arbutus Biopharma Corp. in a research report on Thursday, May 5th. Zacks Investment Research raised shares of Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Monday, April 25th. Chardan Capital upgraded shares of Arbutus Biopharma Corp. from a “sell” rating to a “neutral” rating and set a $3.25 price objective on the stock in a research note on Thursday, June 16th. Finally, Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Arbutus Biopharma Corp. in a research note on Wednesday, May 4th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.96.

The company’s market cap is $213.58 million. The firm’s 50 day moving average price is $3.72 and its 200-day moving average price is $3.94.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.20. Analysts anticipate that Arbutus Biopharma Corp. will post ($1.49) earnings per share for the current year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.